Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab and DLI for Relapsed B-ALL Post-Transplant
NCT06339775Phase 4Recruiting
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of blinatumomab in Acute B-cell lymphoblastic leukemia (B-ALL). Started Sep 2023; status: recruiting.
02
Drugs
blinatumomab
03
Conditions
Acute B-cell lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT06339775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06339775.